Bellicum Pharmaceuticals, Inc. presented new Phase 1 translational results for BPX-601 at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco. The poster titled “Tumor Infiltration and Cytokine Biomarkers of Prostate Stem Cell Antigen (PSCA)-Directed GoCAR-T Cells in Patients with Advanced Pancreatic Tumors ” presented new data from a cohort treated with BPX-601 and a single dose of rimiducid that showed immunomodulation in both the periphery and tumor microenvironment and provided additional insights into surrogate biomarkers of iMC-mediated GoCAR-T® activity. The poster at ASCO GI presented data from Cohort 5B of the study, consisting of 5 pancreatic cancer patients treated with BPX-601 and a single dose of rimiducid. The primary observations were: BPX-601 GoCAR-T cells exhibited enhanced survival and persistence up to 9 months. Activation of BPX-601 GoCAR-T cells mediated upregulation of immunomodulatory cytokines in patients. BPX-601 GoCAR-T cells infiltrated metastatic pancreatic tumors. Changes in tumor microenvironment gene expression consistent with a productive CAR-T cell immune response were observed in patients treated with BPX-601 GoCAR-T cells activated by rimiducid. Interim clinical results from the trial—including results from cohort 5B—were reported at ASCO on June 1, 2019 and may be found on the Bellicum website under Scientific Publications.